Idorsia Ltd (OTC:IDRSF) will be hosting its First Nine-Month 2023 Earnings Conference Call on October 24, 2023 at 9:00 AM ET. The conference call will feature senior executives, including Andrew Weiss, Senior Vice President, Head of Investor Relations & Corporate Communications; Jean-Paul Clozel, Chief Executive Officer; André Muller, Chief Financial Officer; and Tosh Butt, General Manager and President of Idorsia U.S. Among the conference call participants will be Peter Verdult from Citigroup, Brian Balchin from Jefferies, Rajan Sharma from Goldman Sachs, and Sushila Hernandez from Van Lanschot Kempen.
Andrew Weiss will kick off the webcast by welcoming all participants and reminding them that forward-looking statements will be made during the call. Jean-Paul Clozel will then provide introductory remarks, discussing recent measures taken by the company and the current performance of QUVIVIQ worldwide. André Muller will follow with a presentation of the financial results.
Jean-Paul Clozel will highlight recent developments, including the sale of the Asia-Pacific business (excluding China) for CHF400 million, a reduction in headquarters’ workforce by around 50%, and the reacquisition of worldwide rights to Aprocitentan. He will also discuss the agreement with Janssen for the return of Aprocitentan to Idorsia, emphasizing its potential in addressing hypertension.
Jean-Paul Clozel will then shift the focus to the performance of QUVIVIQ in the U.S., noting that over 275,000 prescriptions have been dispensed since its launch. He will discuss the strategy to drive demand, the addition of QUVIVIQ to national preferred formularies, and the transition from VitaCare to KnippeRx as the specialty pharmacy partner. Clozel will mention the temporary product volume volatility experienced during this transition period but assure that prescription volume is returning to growth. He will also highlight the increase in paid prescriptions and improved access for QUVIVIQ in Europe, specifically in the UK and Germany.
Finally, André Muller will address the need for additional funding in the coming months and present the net sales figures for PIVLAZ and QUVIVIQ. He will emphasize the company’s rich portfolio and the potential for fundraising through partnerships.
The conference call will conclude with a Q&A session, where Tosh Butt and Jean-Yves Chatelan will join to answer questions on the performance of QUVIVIQ in the U.S. and EUCAN region, respectively.
Source link
